Perrigo Co. PLC Stock Soars on Friday, Outperforming Market

🌥️Trending News

Perrigo ($NYSE:PRGO) Co. PLC saw its stock take off on Friday, outperforming the rest of the market in a big way. The company specializes in providing quality, affordable healthcare products to consumers and customers around the world. They specialize in OTC products such as vitamins & supplements, pain relief, oral care, skin care, and more. Perrigo also develops and manufactures prescription generic drugs and active pharmaceutical ingredients (APIs) for other companies.

This surge in stock is likely due to the company’s recent acquisitions and growth in their business operations. With the company’s strong financial performance and commitment to providing high-quality affordable healthcare products, it should come as no surprise that their stock went flying on Friday.

Market Price

The stock opened at $32.2 and closed at $33.2, representing a 3.1% increase from its prior closing price of 32.2. The increase came as a surprise to investors, given the current economic climate and the fact that many other stocks were down throughout the day. Analysts have speculated that the increase in PERRIGO COMPANY‘S stock could be attributed to its strong second-quarter financial results, which were released earlier this month.

The stock has also been buoyed by the company’s recent acquisition of UK-based Omega Pharma, which is expected to further enhance PERRIGO’S portfolio of over-the-counter pharmaceutical products. Overall, the stock’s strong performance on Friday is another indication of the company’s strong fundamentals and resilience in a challenging economic environment. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Perrigo Company. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Perrigo Company. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Perrigo Company. More…

Key Ratios Snapshot

Some of the financial key ratios for Perrigo Company are shown below. More…

Analysis

At GoodWhale, we have conducted an analysis of PERRIGO COMPANY‘s wellbeing. Based on our Star Chart, it is clear that PERRIGO COMPANY is strong in dividend, medium in profitability and weak in asset and growth. After further inspection, we have classified PERRIGO COMPANY as a ‘rhino’, a company that has achieved moderate revenue or earnings growth. It is likely that those looking for a steady stream of income from dividends would be interested in PERRIGO COMPANY due to its strong performance in this area. Additionally, those looking for a stable investment with minimal risk could be drawn to PERRIGO COMPANY, given its medium score for profitability and low score for growth. Finally, with a high health score of 8/10 with regard to its cashflows and debt, PERRIGO COMPANY is capable to pay off debt and fund future operations. For investors who prefer to invest in companies with a good financial standing, PERRIGO COMPANY could be a good choice. More…

Peers

Yuhan Corp, JW Pharmaceutical and Lavipharm SA are all competitors of Perrigo Co PLC.

– Yuhan Corp ($KOSE:000105)

Yuhan Corp is a South Korean conglomerate that operates in the pharmaceutical and chemical industries. It has a market cap of 3.83T as of 2022 and a Return on Equity of 4.29%. The company was founded in 1926 and is headquartered in Seoul. It is one of the largest companies in South Korea and is a major player in the global pharmaceutical market.

– JW Pharmaceutical ($KOSE:001060)

As of 2022, JW Pharmaceutical has a market cap of 396.36B and a Return on Equity of 13.04%. The company is a global pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter medicines.

Summary

Perrigo Company PLC is a global healthcare provider, offering products across a range of therapeutic areas, including over-the-counter (OTC) consumer goods, generic prescription drugs, medical devices, and animal health products. Perrigo has been focusing on improving operational efficiencies and reducing costs, while also making strategic investments in research and development to drive organic growth. Additionally, the company’s recent acquisitions have helped expand its product portfolio and increase revenues. Overall, Perrigo’s recent performance and outlook seem to be encouraging investors to add the company’s stock to their portfolios.